GLP-1 / Triple Agonist
Retatrutide vs Semaglutide: A Data-Only Comparison
Head-to-head efficacy, tolerability, and mechanism — what the Phase III data actually shows when you stack the two trials side by side.
Strong·Apr 2026·2,400w
Independent, cited research on the compounds reshaping medicine — from retatrutide's Phase III data to BPC-157 recovery protocols. No hype. No selling. Just the file.
GLP-1 / Triple Agonist
Head-to-head efficacy, tolerability, and mechanism — what the Phase III data actually shows when you stack the two trials side by side.
Weight Loss Peptides
Widely used, rarely understood. We review every published study on AOD-9604 and separate the real signal from the bodybuilding forum mythology.
Recovery
Arguably the most researched recovery peptide. We examine all available animal and human data on tendon healing, gut repair, and systemic effects.
Growth Hormone
A side-by-side review of the two most popular GHRH/GHRP peptides — mechanism, published data, and why the combination became so widely used.
GLP-1 Science
From incretin mimetics to triple agonists — a clear explainer of the underlying science that drives the entire GLP-1 drug class.
Clinical Trials
NDA timelines, PDUFA dates, and what the TRIUMPH trial programme means for regulatory approval. Everything we know as of April 2026.
Compound Spotlight — April 2026
Eli Lilly's triple agonist targets GLP-1, GIP, and glucagon receptors simultaneously — producing weight loss data that outperforms everything before it. Phase III is done. The NDA is coming.
Read the Full File →